- Trial phase
- Phase 2
- Time to market
- SPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.
- Why 6/10
- The next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027 (~10 months away). SPY002 is one of three major IBD assets at Spyre (alongside SPY001 and SPY003), so while it is a major value driver, the company is not a single-asset binary. The impact score reflects a dated pivotal readout within 6-12 months on a major but not sole pipeline asset.
The next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.
Price Chart
Executive Summary
SPY002 is Spyre Therapeutics' extended half-life anti-TL1A antibody for inflammatory bowel disease, currently in Phase 2 development. In June 2026, it posted positive 12-week induction data from the open-label Part A of the SKYLINE trial in ulcerative colitis, meeting its primary endpoint with a 10.7-point reduction in Robart's Histopathology Index (p<0.0001) and showing 33% clinical remission and 42% endoscopic improvement. The drug's ~75-day half-life could enable quarterly or twice-annual maintenance dosing, a potential advantage over first-generation competitors. The next major catalyst is the SKYLINE Part B combination-therapy data expected in Q3 2027. Spyre has a strong cash position ($1.1B, runway into H2 2029) and broad analyst support (Strong Buy consensus, mean target $122.53). However, the TL1A space is intensely competitive (Roche, Teva/Sanofi, Merck all have programs), and a sibling molecule (SPY072) recently disappointed in rheumatoid arthritis.
How It Works
SPY002 is a lab-engineered antibody that blocks TL1A, a protein that drives inflammation and scarring in the gut. By neutralizing TL1A, the drug aims to reduce the immune overactivity that causes inflammatory bowel disease (ulcerative colitis and Crohn's disease). Its key innovation is an extended half-life (the drug stays in the body longer), which could allow patients to receive injections every 3 to 6 months instead of every few weeks.
Trial Status
SPY002 completed Part A of the Phase 2 SKYLINE trial (open-label, 12-week induction) with positive topline results announced June 15, 2026. Part B of SKYLINE, evaluating pairwise combinations of SPY001, SPY002, and SPY003, is enrolling ahead of schedule with topline induction data expected in Q3 2027. SPY002 has also completed Phase 1 testing in healthy volunteers, demonstrating a ~75-day half-life and supporting quarterly or twice-annual maintenance dosing.
The Two-Sided Case
Upcoming Catalysts
- SKYLINE Part B combination-therapy topline induction data (Q3 2027)
- SPY072 SKYWAY trial additional readouts (ongoing)
- SKYLIGHT trial in hidradenitis suppurativa proof-of-concept data (late 2027/early 2028)
- Potential partnership or licensing interest given the validated three-asset platform
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report